CLDN4 and metastatic carcinoma: These data are impressive to the point of suggesting how the differential diagnosis between PEM and NSCLC, and probably also metastatic carcinomas from different sites, potentially could be performed with a combination of HEG1 clone SKM9-2 (now commercially available) and claudin-4 immunostaining.